Announcement: Successful Implementation of the NEW Specialty Inclusion Program

Program Utilizes Proprietary Clinical Infrastructure to Develop and Maintain an Evidence-Based Approach to Evaluating New Drugs for Formulary Inclusion

MDR’s PBM alternative announced the successful implementation of its specialty inclusion program to maintain broad access for payors, providers, and members to beneficial medications at an affordable cost. The program underscores clinical infrastructure and heritage as a company managed and operated predominantly by healthcare professionals, pharmacists, and certified pharmacy technicians.

The Chief Pharmacy Officer, says, "The Specialty Inclusion program's capability is a vital and important new tool in the company’s ability to appropriately manage the utilization of the plethora of drugs being brought to market. It allows us to ensure that drugs with sufficient clinical effectiveness data (e.g., drugs that will be useful to the population served in actual practice) are available for members and payors."

MDRMay 10, 2024